Sign Up to like & get
recommendations!
0
Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-002444
Abstract: Background Bispecific T cell engagers represent the majority of bispecific antibodies (BsAbs) entering the clinic to treat metastatic cancer. The ability to apply these agents safely and efficaciously in the clinic, particularly for solid tumors,…
read more here.
Keywords:
cell engaging;
engaging bsabs;
affinity;
cd3 affinity ... See more keywords